AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth

Core Viewpoint - AbbVie (ABBV) is anticipated to report a year-over-year increase in earnings and revenues for the quarter ended December 2025, with earnings expected to be $3.02 per share, reflecting a +39.8% change, and revenues projected at $16.38 billion, up 8.5% from the previous year [1][3]. Earnings Expectations - The upcoming earnings report is scheduled for February 4, and the stock may rise if the reported figures exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised 0.32% higher in the last 30 days, indicating a slight positive adjustment from analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that AbbVie has a negative Earnings ESP of -12.44%, suggesting analysts have become bearish on the company's earnings prospects [12]. - Despite the negative Earnings ESP, AbbVie holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [12]. Historical Performance - AbbVie has a history of beating consensus EPS estimates, having done so in the last four quarters, with a recent surprise of +5.08% when it reported earnings of $1.86 per share against an expectation of $1.77 [13][14]. Industry Context - In the broader pharmaceutical industry, Merck (MRK) is also expected to report earnings of $2.04 per share for the same quarter, reflecting a year-over-year change of +18.6%, with revenues projected at $16.19 billion, up 3.6% [18]. - Merck's consensus EPS estimate has been revised down by 85.2% over the last 30 days, and it currently has an Earnings ESP of +0.33% but holds a Zacks Rank of 4, complicating predictions for an earnings beat [19][20].